IGC Pharma Inc. (IGC)
NYSE · Healthcare
IGC Pharma Inc. EBITDA 2011–2025
IGC Pharma Inc. annual/quarterly ebitda history and growth rate from 2011 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- IGC Pharma Inc. ebitda for the quarter ending March 31, 2026 was -2.4 M, a 90.63% increase year-over-year.
- IGC Pharma Inc. ebitda for the twelve months ending March 31, 2026 was -7.7 M, a 10.08% decrease year-over-year.
- IGC Pharma Inc. annual ebitda for 2025 was -6.8 M, a 25.47% decrease from 2024.
- IGC Pharma Inc. annual ebitda for 2024 was -9.2 M, a 16.06% decrease from 2023.
- IGC Pharma Inc. annual ebitda for 2023 was -10.9 M, a 26.14% decrease from 2022.
- IGC Pharma Inc. annual ebitda for 2022 was -14.8 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
IGC Pharma Inc. EBITDA — FAQ
IGC Pharma Inc. (IGC) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IGC's ebitda history?
The chart and table above show IGC Pharma Inc.'s ebitda by year and by quarter, including the growth rate.